Value
6.1/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 7.7 |
| Fwd P/E | 1.0 |
| PEG | 10.0 |
| Analyst target | 4.0 |
- ▸Forward P/E: 100.7x
- ▸PEG: 0.15
ATRC · Why this verdict
Why AtriCure (ATRC) is rated HOLD
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictHOLD
Overall score6.1/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
AtriCure has demonstrated consistent earnings execution with three consecutive beats and substantial analyst upside of 46%, but a confirmed price downtrend and elevated options hedging create near-term headwinds that must resolve before the fundamental case translates into price appreciation.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company has delivered three consecutive earnings beats with an average positive surprise of roughly 132%, consistently clearing analyst expectations by wide margins — a signal of disciplined cost management and execution above guidance. Earnings | EPS beats continue for at least 2 more consecutive quarters, with average quarterly surprise staying above 50%. | →Stable |
| CounterThe most recent reported quarter showed an unknown actual result, leaving the streak unconfirmed. Sustained large surprises can reflect overly conservative guidance rather than genuine operational outperformance. | ||
Despite reporting GAAP losses, the company generates positive free cash flow — roughly 7% FCF margin and a 2.9% FCF yield — demonstrating that the business produces real economic cash while investing heavily for growth. Quality breakdown | Free cash flow margin expands beyond 10% as revenue scales and investment intensity normalizes. | →Stable |
| CounterA strong financial health score and positive free cash flow sit alongside a quality composite that scores below average, and a Rule of 40 score of 22 falls well short of the threshold for medtech growth businesses — suggesting the growth-adjusted profitability profile is not yet compelling. | ||
At the current price, the stock trades roughly 46% below the consensus analyst price target, producing a risk/reward ratio of approximately 6.6-to-1 in favor of bulls — a setup that offers material asymmetry even under a cautious scenario. Price targets | Price advances at least 20% toward the analyst target over 12 months as the downtrend resolves. | ↑Improving |
| CounterAnalyst targets frequently lag price dislocations; the confirmed downtrend suggests the market is discounting risks the sell-side has not yet reflected in target reductions. | ||
The stock is trading below its 200-day moving average with the average declining at approximately 2.9% per month, constituting a confirmed downtrend that historically pressures price until the slope reverses. Momentum breakdown | The 200-day moving average slope turns positive and the stock closes above the moving average for 3 consecutive weeks. | →Stable |
| CounterVolume accumulation is rising and the MACD is improving, which suggests the downtrend may be in its later stages rather than accelerating. | ||
A put/call ratio of 3.33 and implied volatility of 138% signal that options participants are positioning heavily for further downside, creating an overhang that may delay near-term price recovery even if fundamentals improve. Risk breakdown | Put/call ratio normalizes below 1.5 as sentiment improves alongside fundamental progress. | ↑Improving |
| CounterExtreme put/call ratios can mark sentiment extremes and serve as contrarian indicators — if the bearish positioning becomes sufficiently crowded, even a modest catalyst can trigger a rapid mean-reversion squeeze. | ||
The company has delivered three consecutive earnings beats with an average positive surprise of roughly 132%, consistently clearing analyst expectations by wide margins — a signal of disciplined cost management and execution above guidance.
→StableEarnings
- Expectation
- EPS beats continue for at least 2 more consecutive quarters, with average quarterly surprise staying above 50%.
CounterThe most recent reported quarter showed an unknown actual result, leaving the streak unconfirmed. Sustained large surprises can reflect overly conservative guidance rather than genuine operational outperformance.
Despite reporting GAAP losses, the company generates positive free cash flow — roughly 7% FCF margin and a 2.9% FCF yield — demonstrating that the business produces real economic cash while investing heavily for growth.
→StableQuality breakdown
- Expectation
- Free cash flow margin expands beyond 10% as revenue scales and investment intensity normalizes.
CounterA strong financial health score and positive free cash flow sit alongside a quality composite that scores below average, and a Rule of 40 score of 22 falls well short of the threshold for medtech growth businesses — suggesting the growth-adjusted profitability profile is not yet compelling.
At the current price, the stock trades roughly 46% below the consensus analyst price target, producing a risk/reward ratio of approximately 6.6-to-1 in favor of bulls — a setup that offers material asymmetry even under a cautious scenario.
↑ImprovingPrice targets
- Expectation
- Price advances at least 20% toward the analyst target over 12 months as the downtrend resolves.
CounterAnalyst targets frequently lag price dislocations; the confirmed downtrend suggests the market is discounting risks the sell-side has not yet reflected in target reductions.
The stock is trading below its 200-day moving average with the average declining at approximately 2.9% per month, constituting a confirmed downtrend that historically pressures price until the slope reverses.
→StableMomentum breakdown
- Expectation
- The 200-day moving average slope turns positive and the stock closes above the moving average for 3 consecutive weeks.
CounterVolume accumulation is rising and the MACD is improving, which suggests the downtrend may be in its later stages rather than accelerating.
A put/call ratio of 3.33 and implied volatility of 138% signal that options participants are positioning heavily for further downside, creating an overhang that may delay near-term price recovery even if fundamentals improve.
↑ImprovingRisk breakdown
- Expectation
- Put/call ratio normalizes below 1.5 as sentiment improves alongside fundamental progress.
CounterExtreme put/call ratios can mark sentiment extremes and serve as contrarian indicators — if the bearish positioning becomes sufficiently crowded, even a modest catalyst can trigger a rapid mean-reversion squeeze.
Per-dimension breakdown
Quality
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.7 |
| ROA | 0.8 |
| Gross margin | 10.0 |
| Op margin | 2.5 |
| Net margin | 0.9 |
| Current ratio | 8.8 |
| FCF quality | 10.0 |
| Moat | 7.9 |
| Rule of 40 | 3.0 |
| Piotroski F | 10.0 |
- ▸Excellent cash conversion: 463% FCF/NI
- ▸Wide economic moat
- ▸Rule of 40: 21 (fail)
- ▸Strong Piotroski F-Score: 9/9
Growth
7.8/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 5.7 |
| EPS growth | 10.0 |
Momentum
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.2 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Overbought (RSI 76)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 6.9 |
| Price target | 6.0 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (9.0) — signal dampened
Insider
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 9.5 |
| notable moves | 7.0 |
- ▸Modest insider selling — $1,505,092 (0.068% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 2.2 |
| quality rank | 4.2 |
| growth rank | 7.1 |
Technical
3.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.2 |
| support resistance | 0.1 |
| 52w position | 9.9 |
Risk (lower is worse)
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.0 |
| days to cover | 6.7 |
| volatility | 2.5 |
| implied vol | 0.4 |
| beta | 6.1 |
| debt equity | 9.4 |
- ▸High IV: 78%
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Strong earnings: 3B/0M
How the verdict was assembled
Engine trigger
Maintain position. Not compelling to add more.
Engine technical detail
verdict_path:
L4:PATH_F_HOLDPassed (6)
- MOMENTUM:6.6>=5.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:74d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.5=NEGATIVE
Warning (1)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
Reward-to-Risk
-0.47
Upside
-7.0%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilityAggressive — MCap $2.2B<$5B
Investment implication
None of the engine's positive-conviction paths (C-quality, D-momentum) triggered — the F-path HOLD reflects balanced signals. Strongest-cleared gate: MOMENTUM:6.6>=5.5. Top dim: Growth at 7.8; weakest: Technical at 3.7. No conviction either direction.
The strongest dimensions are Growth at 7.8, Catalyst at 7.5, and Momentum at 6.6; the weakest are Technical at 3.7, Peer rank at 5.0, and Risk (lower is worse) at 5.2. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -0.47 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Earnings Beat Streak Execution
Trip ifEPS surprise falls below 0% for 2 consecutive quarters.
- P2Analyst Upside Favorable Asymmetry
Trip ifAnalyst consensus target falls below $35, compressing upside to take profit below 25%.
- P3Confirmed Downtrend Technical Overhang
Trip if200-day moving average slope turns positive and stock closes above the 200-day moving average for 3 consecutive weeks.
- P4Fcf Positive Despite Gaap Losses
Trip ifFree cash flow falls below $0 for 2 consecutive quarters.
- P5Elevated Options Hedging Pressure
Trip ifPut/call ratio compresses below 1.0 for 4 consecutive weeks.